Psychedelic medicine is back in the headlines after the Trump administration moved to accelerate research and access for compounds such as ibogaine and psilocybin. An FDA public meeting on safety and access standards is the latest step. Reuters summarized the landscape.

Most of these drugs are still Schedule I in the United States. That legal status gets the attention. It should not hide a simpler fact: one related treatment is already used in clinics, already studied at scale, and does not require Congress or the DEA to reschedule psilocybin first. Patients comparing ketamine Miami and ketamine Aventura options can start there.

The administration wants faster development of psychedelic-assisted therapies. The FDA is being asked to set clearer rules for how these drugs would be used if they leave experimental trials. Until then, almost all classic psychedelics remain in the same legal class as heroin: no accepted medical use, high abuse potential. That is why clinics cannot stock psilocybin or MDMA the way they stock an approved antidepressant.

The best data so far come from patients with treatment-resistant depression or PTSD who have already not gotten enough from standard care. Early-stage trials are also looking at substance use disorders, anxiety, OCD, borderline personality disorder, and some chronic-pain conditions. That is promising and still incomplete. “Promising” is not the same as approved and available on every block.

Unlike a daily SSRI taken at home, psychedelic-assisted therapy is usually a small number of supervised sessions plus intensive psychotherapy. The drugs act on receptors that help the brain reorganize connections. The setting and the therapy are part of the treatment, not an afterthought. That model is hard to scale, which is one reason regulators are cautious.

In the U.S. and Europe, synthetic psilocybin for treatment-resistant depression is the lead candidate. Compass Pathways’ COMP360 reduced symptoms within days in late-stage trials, with effects lasting months for some patients. The company has said it aims to file with the FDA in late 2026. Other programs include LSD-based drugs for anxiety, naturally derived psilocybin, 5-MeO-DMT, and ibogaine research after small veteran studies. MDMA for PTSD looked strong in Phase 3 work, but the FDA rejected Lykos Therapeutics’ application in 2024 and asked for another trial. Australia has authorized MDMA for PTSD and psilocybin for treatment-resistant depression. The U.S. has not.

Sessions can bring acute anxiety, panic, or confusion. An estimated 10–15% of patients report longer-term negative effects. Psychosis or mania is a particular concern in people with bipolar disorder, schizophrenia, or a strong family history. Physical risks include nausea with psilocybin, blood-pressure and heart-rate spikes with MDMA, and dangerous heart-rhythm problems with ibogaine. Those risks rise when the drugs are used outside a medical setting. That is the core of the FDA’s current debate: access versus uncontrolled use.

While classic psychedelics sit in Schedule I, ketamine and esketamine are already in medical use. Johnson & Johnson’s esketamine nasal spray, Spravato, is FDA-approved for treatment-resistant depression and suicidal ideation. Ketamine itself is approved as an anesthetic and is used off-label for depression in clinics across the country. It is often grouped with “non-classical” psychedelic medicines because it can produce mind-altering effects some patients find therapeutic.

The research base is large compared with ibogaine or unapproved psilocybin. That does not make ketamine risk-free or a cure. It does mean the “nothing is available until Washington changes the schedules” story is incomplete. IV ketamine therapy and other modalities are offered at our locally owned Aventura clinic, serving Miami, North Miami, and South Florida. Fully guided sessions are available.

Watch the pipeline. Psilocybin may reach the FDA later this year or next. Ibogaine research may move faster under political pressure. MDMA’s path is stuck until another trial is done. Meanwhile, ketamine and esketamine are the treatments that already exist inside the current legal system, with clinic protocols and a substantial medical literature. Policy can change the future of psychedelic care. It does not have to be the only door patients use right now.